Evidence map›Paper›PMID 40088403›Full record

ArticleAnnals of nuclear medicine2025

Metabolic tumor parameters on

Shuhui Huang, Yaowen Zhang, Wei Zhang, Tian Tian, Hongyuan Dai, Mengfang Qi, Minggang Su, Hao Zeng, Rui Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shuhui Huang *Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Yaowen Zhang *Department of Urology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Wei ZhangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Tian TianDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Hongyuan DaiDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Mengfang QiDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Minggang SuDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China.
Hao ZengDepartment of Urology, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China. zengh@scu.edu.cn.
Rui HuangDepartment of Nuclear Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, People's Republic of China. huang_rui@scu.edu.cn.ORCID http://orcid.org/0000-0003-3191-0528

Funding

National Natural Science Foundation of China 81972502National Natural Science Foundation of China 82172785National Natural Science Foundation of China 82373422
6 · The paper itself

Abstract

objectiveThis study aimed to comprehensively evaluate the performance of fluorine-18 fluorodeoxyglucose (

methodsTwenty-nine patients with FHRCC were prospectively enrolled from May 2020 to February 2023 for

resultsPrimary/recurrent and metastatic lesions showed FDG avidity, without metabolic differences between them. In our analysis, SUVmax of whole body (WB-SUVmax), SUVpeak of whole body (WB-SUVpeak), MTV of whole body (WB-MTV), and TLG of whole body (WB-TLG) were associated with the expression of PD-L1. The optimal cut-off values of WB-SUVmax, WB-SUVpeak, WB-MTV, and WB-TLG for predicting positive PD-L1 expression were 9.86 (AUC 0.814), 6.92 (AUC 0.848), 19.61 cm

conclusions

Indexed as

B7-H1 AntigenCarcinoma, Renal CellFluorodeoxyglucose F18Fumarate HydrataseGene Expression Regulation, NeoplasticKidney NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedFemaleHumansMaleMiddle AgedPrognosisB7-H1 AntigenCD274 protein, humanFluorodeoxyglucose F18Fumarate HydrataseFluorodeoxyglucoseFumarate hydratase-deficient renal cell carcinomaMetabolic parametersPositron emission tomography/computed tomographyProgrammed cell death ligand 1

Identifiers

PMID40088403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.